Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc R&D Day Transcript

Oct 18, 2023 / 12:30PM GMT
Release Date Price: €24.4
Jack A. Khattar
Supernus Pharmaceuticals, Inc. - Founder, President, CEO, Secretary & Director

Okay. Good morning, and thank you so much for joining us today. We're very excited about the R&D Day and what we're going to be sharing with you about the future of Supernus.

Now before I get started, I just want to remind everyone that we will be making forward-looking statements throughout the day, so please check our SEC filings for all the risk factors associated with our business.

As far as our agenda today, I'll be making very brief introductions and going through a brief corporate overview, and then we'll get into the details behind some of the key product candidates that we have in our pipeline. We will have a couple of slides on Qelbree at the beginning in the R&D setting, and then we'll get into 820 -- SPN-820 for depression. We'll have a small Q&A session behind 820. We'll get into the details behind SPN-817. We'll also have a Q&A session after that. And then we will share with you some early data we have on SPN-443 for ADHD and SPN-446 for narcolepsy. And we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot